. Author manuscript; available in PMC: 2021 Apr 14.

Published in final edited form as: Hematol Med Oncol. 2019 Jun 28;4:1000183. doi: 10.15761/hmo.1000183

Table 2. Drugs already approved by FDA for other application that are now studied or under clinical trials to for hematological malignancies applications.

Name	Composition		Disease	Year-Target FDA approval	References
Name	NPs	Active substances	Disease	Year-Target FDA approval	References
DaunoXome	Liposomes	Daunorubicin	Acute Myeloid/Lymphoblastic Leukemia	1996-HIV Kaposi’s sarcoma	[178–180]
Myocet	Liposomes	Doxorubicin	Lymphoma	2000-metastatic breast cancer	[181,182]
Abraxane	Albumin	Paclitaxel	Lymphoma	2005-breast, lung and pancreatic cancer	[183]